The TRAVERSE trial showed testosterone replacement treatment was noninferior to placebo with regard to the risk of major adverse cardiac events. The Food and Drug Administration (FDA) is requiring ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results